| Zacks Company Profile for Shionogi & Co., Ltd. Unsponsored ADR (SGIOY : OTC) |
|
|
| |
| Company Description |
| Shionogi & Co., Ltd. engages in the research, development, manufacture and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. Shionogi & Co., Ltd. is based in Osaka, Japan.
Number of Employees: 4,959 |
|
|
| |
| Price / Volume Information |
| Yesterday's Closing Price: $8.47 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 134,839 shares |
| Shares Outstanding: 1,701.38 (millions) |
| Market Capitalization: $14,410.68 (millions) |
| Beta: 0.20 |
| 52 Week High: $9.23 |
| 52 Week Low: $6.53 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
6.14% |
3.36% |
| 12 Week |
-5.15% |
-9.08% |
| Year To Date |
21.70% |
6.38% |
|
|
|
|
| |
| Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
1-8 DOSHOMACHI 3-CHOME - OSAKA,M0 541-0045 JPN |
ph: 816-620-2216 fax: - |
None |
http://www.shionogi.com |
|
|
| |
| General Corporate Information |
Officers
IsaoTeshirogi - President and CEO
Keiichi Ando - Chairperson
Takuko Sawada - Director and Vice Chairperson of the Board
Hiroshi Ozaki - Director
Fumi Takatsuki - Director
|
|
Peer Information
Shionogi & Co., Ltd. Unsponsored ADR (GSAC)
Shionogi & Co., Ltd. Unsponsored ADR (CASI)
Shionogi & Co., Ltd. Unsponsored ADR (ALCD.)
Shionogi & Co., Ltd. Unsponsored ADR (OMNN)
Shionogi & Co., Ltd. Unsponsored ADR (CGPI.)
Shionogi & Co., Ltd. Unsponsored ADR (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 824667109
SIC: 8880
|
|
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 01/30/26
|
|
Share - Related Items
Shares Outstanding: 1,701.38
Most Recent Split Date: 10.00 (1.50:1)
Beta: 0.20
Market Capitalization: $14,410.68 (millions)
|
|
|
|
|
| |
| EPS Information |
Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 1.81% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.15 |
| Current Fiscal Year EPS Consensus Estimate: $0.71 |
Payout Ratio: 0.24 |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: 0.09 |
| Estmated Long-Term EPS Growth Rate: 6.05% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 01/30/26 |
|
|
|
| |